Citius Pharmaceuticals (Nasdaq:CTXR) - Stock Price, News & Analysis

CTXR Stock Overview

A late-stage biopharmaceutical company, engages in the development and commercialization of critical care products.

CTXR fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 98.6% below our estimate of its fair value

Earnings are forecast to grow 65.59% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shareholders have been diluted in the past year

Volatile share price over the past 3 months

Citius Pharmaceuticals, Inc. Competitors

Regencell Bioscience Holdings

NasdaqCM:RGC

US$94.0m

Oramed Pharmaceuticals

NasdaqCM:ORMP

US$97.8m

Journey Medical

NasdaqCM:DERM

US$108.0m

Eton Pharmaceuticals

NasdaqGM:ETON

US$118.8m

Price History & Performance

Summary of all time highs, changes and price drops for Citius Pharmaceuticals
Historical stock prices
Current Share Price	US$0.57
52 Week High	US$1.07
52 Week Low	US$0.48
Beta	1.68
11 Month Change	-37.02%
3 Month Change	-18.28%
1 Year Change	-38.78%
33 Year Change	-72.86%
5 Year Change	-54.40%
Change since IPO	-96.20%

Recent updates

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully

Apr 06

We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate

Dec 08

Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?

Aug 01

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Apr 12

Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Dec 25

Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK

Sep 28

Citius Pharmaceuticals GAAP EPS of -$0.06

Aug 11

Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

Aug 05

Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK

Jul 12

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Dec 04

Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization

Sep 26

Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth

Aug 28

Citius: Halt For Superiority On The Horizon

Jun 15

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

May 15

Citius Pharmaceuticals shares rise in anticipation of Mino-Lok phase 3 results

Apr 26

Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Deliver On Growth Plans?

Dec 18

Shareholder Returns

	CTXR	US Pharmaceuticals	US Market
7D	-4.2%	1.1%	0.06%
1Y	-38.8%	20.0%	22.6%

Return vs Industry: CTXR underperformed the US Pharmaceuticals industry which returned 19.3% over the past year.

Return vs Market: CTXR underperformed the US Market which returned 22.2% over the past year.

Price Volatility

Is CTXR's price volatile compared to industry and market?
CTXR volatility
CTXR Average Weekly Movement	14.2%
Pharmaceuticals Industry Average Movement	10.1%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

Stable Share Price: CTXR's share price has been volatile over the past 3 months.

Volatility Over Time: CTXR's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2007	22	Leonard Mazur	citiuspharma.com

Citius Pharmaceuticals, Inc., a late-stage biopharmaceutical company, engages in the development and commercialization of critical care products. The company's diversified pipeline includes two late-stage product candidates, Mino-Lok and LYMPHIR. The company has enrollment in a Phase 3 pivotal trial of Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections.

Citius Pharmaceuticals, Inc. Fundamentals Summary

How do Citius Pharmaceuticals's earnings and revenue compare to its market cap?
CTXR fundamental statistics
Market cap	US$102.40m
Earnings (TTM)	-US$39.77m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-2.6x

P/E Ratio

Is CTXR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CTXR income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$39.77m
Earnings	-US$39.77m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.22
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did CTXR perform over the long term?

See historical performance and comparison

CTXR Stock Overview

Rewards

Risk Analysis

Citius Pharmaceuticals, Inc. Competitors

NasdaqCM:RGC

US$94.0m

NasdaqCM:ORMP

US$97.8m

NasdaqCM:DERM

US$108.0m

NasdaqGM:ETON

US$118.8m

Price History & Performance

Recent News & Updates

Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Citius Pharmaceuticals, Inc. Receives FDA Approval for LYMPHIR Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Price target increased by 22% to US$4.67

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million.

Recent updates

Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Citius Pharmaceuticals, Inc. Receives FDA Approval for LYMPHIR Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Price target increased by 22% to US$4.67

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million.

Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully

New minor risk - Share price stability

The Nasdaq Stock Market LLC Grants Citius Pharmaceuticals' Request for an Extension through September 9, 2024 to Evidence Compliance with the Bid Price Rule Pursuant to Nasdaq Listing Rule 5550(a)(2)

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Announces the Resubmission of the Biologics License Application to the U.S. Food and Drug Administration for Lymphir

New minor risk - Market cap size

Citius Pharmaceuticals, Inc., Annual General Meeting, Mar 12, 2024

Citius Pharmaceuticals, Inc. Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage Catheters

New major risk - Financial position

New minor risk - Profitability

We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate

Citius Pharmaceuticals, Inc. Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor

New minor risk - Share price stability

Citius Pharmaceuticals, Inc. Announces Changes to its Audit Committee

Citius Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Stock Market

Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration Regarding the Planned Resubmission of the BLA for LYMPHIR

Citius Pharmaceuticals, Inc. Reaches 92 Event Milestone in Mino-Lok Phase 3 Trial

Price target decreased by 21% to US$3.17

Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?

Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals, Inc. Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids

Consensus EPS estimates fall by 24%

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Forecast breakeven date pushed back to 2025

Price target increased by 25% to US$5.00

Forecast breakeven date pushed back to 2025

Citius Pharmaceuticals, Inc. Appoints Dennis M. McGrath to Board of Directors

Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Citius Pharmaceuticals, Inc., Annual General Meeting, Feb 07, 2023

Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

Price target decreased to US$3.60

Insufficient new directors

Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK

Citius Pharmaceuticals GAAP EPS of -$0.06

Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma

Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK

Citius Pharmaceuticals: Hoping For A Turnaround Strategy

Price target increased to US$4.00

Insufficient new directors

Citius Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Citius Pharmaceuticals, Inc. Announces Executive Changes

Critical Care Biopharma - Citius Pharmaceuticals

Forecast breakeven date pushed back to 2024

Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/Ontak (E7777)

Citius: 2022 Is A Year Of Catalysts

Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Forecast breakeven date moved forward to 2023

Citius Pharmaceuticals, Inc. Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization